A Time for Gratitude
As I write this column, it is early fall, and I am contemplating the upcoming ASH Annual Meeting & Exhibition in San Diego and the end of this year whe
Related Articles
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+…
Advancing Drug Development in Myelodysplastic Syndromes
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of all
Generic Platinum Chemotherapy Shortages Did Not Increase Deaths
A national data analysis published by researchers from Penn Medicine reported that short-term mortality was not impacted for patients with advanced cancers during the shortage…
AACR-QuadW Foundation Sarcoma Research Fellowship in Memory of Willie Tichenor
The one-year grant of $50,000 supports a postdoctoral or clinical research fellow conducting translational or clinical sarcoma research.
Addressing Tumor-Specific Training Needs of the CNS in Uro-Oncology – Oncology Nurse Advisor
A discussion paper on the role of the clinical nurse specialist in uro-oncology noted challenges due to a lack of consistent definition of the role,…
An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA
Key PointsWe characterized erythropoiesis and iron metabolism in a new model of XLSA, showing ring sideroblasts and mitochondrial iron accumulation.We used
Registration
The 2025 Tandem Meetings feature both in-person and digital programming for attendees to choose the experience that best fits their schedule, budget and needs.
Volume 85 Issue 1 | Cancer Research | American Association for Cancer Research
Cancer Research | 85 | 1 | January 2025
Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER+ Breast Cancer Treatment
Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen receptor-positive/HER2-negative metastatic breast cancer treatment.
